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Summary 
Surveillance for viral hepatitis is needed to direct and evaluate prevention 
and control activities. CDC recommends that all states and territories 
conduct surveillance for acute viral hepatitis, including hepatitis A, B, C, 
and non-ABC hepatitis. In addition, states and territories should consider 
establishing computerized databases of persons who test positive for 
hepatitis B surface antigen (HBsAg) or antibody to hepatitis C virus (anti-
HCV) to facilitate the notification, counseling and management of persons 
with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. 
The purpose of this document is to 1) provide guidance to clinicians, state 
and local health departments, and other health agencies regarding case 
ascertainment, reporting, investigation, and follow-up of persons with 
acute viral hepatitis; and 2) provide a framework for the development of 
systems for identifying and following up persons who may have chronic 
HBV or HCV infections. These guidelines describe the essential 
elements and best practices for conducting surveillance for viral hepatitis, 
and were developed based on consultation with representatives from 
state and local health departments who met in Atlanta in January 1999. 
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In 2000, there were 
approximately 25,000 
cases of acute viral 
hepatitis reported 
nationwide, including 
14,000 cases of 
hepatitis A and 8,000 
cases of hepatitis B. 
In addition, 1.25 
million persons are 
chronically infected 





The primary goals of conducting surveillance for viral hepatitis are 
to direct prevention and control activities for these diseases and to 
evaluate the impact of these activities. In 2000, there were 
approximately 25,000 cases of acute viral hepatitis reported nationwide, 
including 14,000 cases of hepatitis A and 8,000 cases of hepatitis B. In 
addition, 1.25 million persons are chronically infected with HBV and 2.7 
million are chronically infected with HCV. Any person with a hepatitis 
virus infection is a potential source of infection to others. The 
investigation of infected persons can prevent further transmission by 
identifying contacts who require vaccination or other preventive 
interventions and by detecting outbreaks, determining the cause, and 
implementing appropriate control and prevention measures. Aspects of 
the epidemiology and prevention specific for each type of viral hepatitis 
need to be considered in developing surveillance systems for these 
diseases. Surveillance overall helps to accomplish these goals by 
providing information to: 
•	 Monitor trends in incidence of and risk factors for disease 
•	 Assess burden of disease 
•	 Identify infected persons requiring counseling and medical follow-up 
•	 Identify contacts of infected persons requiring counseling and/or post 
exposure prophylaxis 
•	 Identify and control outbreaks
Information on cases of viral hepatitis reported nationally has been 
maintained at CDC in two surveillance systems. Information collected by 
the National Notifiable Disease Surveillance System (NNDSS) includes 
diagnosis, event dates (e.g., illness onset), and basic demographic data 
(e.g., state, county, age, race, ethnicity). Additional information collected 
by the Viral Hepatitis Surveillance Program (VHSP) includes clinical 
features, serologic test results, and risk factors for infection. This 
information is needed to confirm the diagnosis, determine a source of 
infection, and identify others at risk of infection that would benefit from 
preventive intervention. 
In 1989, a consolidation of VHSP and NNDSS was initiated with 
efforts to have all acute viral hepatitis surveillance data reported 
electronically to a single system, the National Electronic 
Telecommunications System for Surveillance (NETSS). Data entry 
screens are available in NETSS that include all of the information 
requested for both NNDSS and the VHSP. 
Not all states have participated in VHSP, and among states that have 
participated in VHSP, the proportion of cases reported to both NNDSS 
and VHSP has been variable. In addition, several participating states 
have continued to report data only on the paper copy of the VHSP form, 
rather than electronically. Paper reporting via VHSP was discontinued as 
of January 2002. Thus, all information on reported cases of acute viral 
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hepatitis are now received and maintained through a single unified 
electronic reporting system. Improving the completeness of case reports 
made through this system will require further efforts by CDC and state 
health departments. 
As an element of the planned National Electronic Data 
Surveillance Systems (NEDSS), substantial changes in the structure and 
function of NETSS are expected. The development of a person-based 
system that collects and stores public health information according to 
widely used, standardized definitions and formats and that uses unique 
identifiers to link information from different disease reports and other 
health data sources will significantly enhance the capacity to conduct 
surveillance for viral hepatitis. 
To date, nationwide surveillance efforts for viral hepatitis have 
focused on cases of newly acquired clinically apparent disease, and 
historically, most cases of acute viral hepatitis have been identified on the 
basis of a clinician’s report of a patient with an illness compatible with 
acute hepatitis. With the implementation of laboratory reporting 
requirements in many states, laboratory-based reporting of serologic 
markers for viral hepatitis is an increasingly common route by which 
suspected cases are identified to state and local health departments. 
Although laboratory-based reporting can increase the completeness and 
timeliness of case identification, it also identifies asymptomatic individuals 
with newly acquired infections, individuals with chronic infection, and 
individuals for whom there is insufficient information to verify the 
diagnosis based on laboratory testing alone. 
Although asymptomatic individuals with newly acquired infections 
represent incident infections, they have not been included as reportable 
conditions. However, as the incidence of all types of acute viral hepatitis 
declines, the ascertainment and reporting of all persons testing positive 
for serologic markers of recent infection with hepatitis viruses will be 
necessary to monitor their incidences. When the definitions and 
categories for reporting cases of acute viral hepatitis are expanded to 
include those identified by laboratory test results alone, it will be important 
to distinguish symptomatic from asymptomatic individuals. This is 
because the numbers of asymptomatic persons identified can be highly 
variable depending on testing practices, and result in artificial differences 
in incidence both temporally and geographically. In addition, the ability to 
identify such individuals is primarily limited to HAV and HBV infections, for 
which IgM antibody assays specific for acute infection are available. No 
serologic marker is available for acute HCV infection, thus, the incidence 
of HAV or HBV infections relative to HCV infection would not accurately 
reflect their true relationships. The full implications of expanding 
surveillance case definitions to include asymptomatic individuals will not 
be known until these strategies are implemented. 
Laboratory-based reporting also identifies HBV or HCV infected 
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Rates of hepatitis A 
are now the lowest 
ever recorded. 
Nevertheless, 
hepatitis A remains 
one of the most 
frequently reported 
vaccine preventable 
diseases in the United 
States 
persons with chronic infection. Although previously not included among 
nationally notifiable conditions, the public health importance of chronic 
viral hepatitis infections dictates that they be added. Several states and 
counties have established viral hepatitis infection databases for persons 
testing positive for HBsAg or anti-HCV, but their experience indicates that 
managing large numbers of HBsAg positive and anti-HCV positive 
laboratory reports has the potential to overwhelm a surveillance system 
and divert scarce resources into data management rather than disease 
prevention. The expected integration of functions and standards in 
NEDSS that facilitate the implementation of such databases will enhance 
capacity to manage and monitor these reports. Further assessment at the 
state and local level is needed to determine the most feasible and useful 




Periodic epidemics of hepatitis A have occurred in the United States 
approximately every decade; the last nationwide epidemic occurred in 
1995 1. Since then, rates of hepatitis A have declined precipitously and 
are now the lowest ever recorded. Nevertheless, hepatitis A remains one 
of the most frequently reported vaccine preventable diseases in the 
United States. In 2000, a total of 13,397 cases of hepatitis A were 
reported to CDC1, which, when corrected for underreporting and 
asymptomatic infections, represents an estimated 57,000 cases and 
143,000 infections. 
Historically, incidence of hepatitis A has varied by race/ethnicity with 
the highest rates among American Indians/Alaska Natives and rates 
among Hispanics that were higher than among non-Hispanics. However, 
rates among American Indians/Alaska Natives have dropped dramatically 
since the implementation of widespread routine hepatitis A vaccination in 
high rate Native American communities and are now the same as for 
other races. Rates among Hispanics remain higher than among non-
Hispanics. The highest rates of reported disease have been among 
children 5-14 years of age, and although disease rates in this group have 
decreased substantially in recent years and are similar to those among 
adults, $25 percent of reported cases are in persons <20 years of age. 
Asymptomatic or unrecognized infections occurring in young children are 
often a source of infection to others. Most cases of hepatitis A result from 
person-to-person transmission during community-wide epidemics in 
which children play a critical role in sustaining hepatitis A virus (HAV) 
transmission. 
Prevention strategies
Hepatitis A vaccine has been licensed in the United States 
since 1995, and in 1996 routine childhood hepatitis A vaccination was 
recommended in communities with the highest hepatitis A rates, which 
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included American Indian, Alaskan Native and selected Hispanic, migrant 
and religious communities. Coincident with the implementation of 
hepatitis A vaccination of children in those communities, there have been 
dramatic reductions in hepatitis A rates in those areas. 
In 1999, the recommendations for routine vaccination of children 
were extended to include children living in states or counties with rates at 
least twice the 1987-1997 national average (i.e. #20 cases per 100,000 
population) 2. It was suggested that vaccination also be considered for 
children living in states or counties with average rates that exceeded the 
1987-1987 national average (i.e., $10-#20 cases per 100,000). 
Reductions in hepatitis A rates in these areas since 1999 suggest that 
routine vaccination is having an impact but further monitoring is needed to 
determine whether these decreased rates are sustained and attributable 
to vaccination. Pre-exposure vaccination is also recommended for 
persons at high risk for hepatitis A including illegal drug users, men who 
have sex with men, persons traveling to countries where HAV is endemic, 
and persons with occupational risk of infection (i.e., persons who work 
with HAV-infected primates or with HAV in a research laboratory), as well 
as for persons with chronic liver disease. However, since as many as 
50% of reported cases do not belong to one of these identified risk 
groups, vaccination of persons in these groups has little effect on national 
disease rates and does not prevent the majority of cases. 
Surveillance
Because no chronic infection develops after hepatitis A, reported 
cases of acute disease provide a valid measure of ongoing transmission 
and the overall burden of disease due to HAV. Investigation of reported 
cases to determine their characteristics and source for infection provides 
the best information for monitoring trends in transmission patterns. 
Monitoring changes in overall and age-specific disease rates is the only 
means available to assess the effectiveness of hepatitis A vaccination 
programs. 
Demographic and risk factor information collected through 
surveillance can be used to direct ongoing prevention efforts by 
identifying new target groups or areas in which vaccination programs 
should be initiated. Missed opportunities for vaccination can be assessed 
by investigating cases occurring in persons belonging to a group for 
which vaccination is recommended to determine where they have 
received health care and other recommended vaccinations. Intensive 
investigation of cases occurring in persons who received hepatitis A 
vaccine may be used to evaluate the frequency and causes of vaccine 
failure. 
Timely identification of persons with acute hepatitis A allows 
exposed contacts to receive effective prophylaxis to prevent secondary 
spread of HAV. This is important in preventing outbreaks associated with 
day care centers or infected food handlers and to prevent person-to-
person transmission in households and extended family settings and 
                                       
   
 
among sexual contacts. 
 Hepatitis A often occurs in the context of community wide 
epidemics, but outbreaks also occur among persons reporting certain 
behaviors (e.g., men having sex with men, illicit drug use) or exposures 
(e.g., food contaminated with HAV). By investigating reported cases for 
risk factors and recent exposures, groups at increased risk for infection 
can be identified for targeted prevention activities or a potential common 
source can be identified that might have placed additional persons at risk. 
 
The estimated 
number of new 
infections in 2000 
was 81,000, a 
decrease of 70% from 
a peak of 
approximately 
280,000 in the mid-
1980’s
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Hepatitis B
Epidemiologic characteristics   
Acute and chronic HBV infections are a major cause of morbidity 
and mortality in the United States. Acute hepatitis B is one of the most 
commonly reported vaccine preventable diseases; in 2000, 8036 cases 
were reported 1. However, because most newly infected persons are 
asymptomatic 3, and because even symptomatic persons are 
underreported 4, reported hepatitis B cases markedly underestimate the 
incidence of HBV infection. Based on catalytic modeling of data from the 
second and third National Health and Nutrition Examination Surveys, the 
estimated number of new infections in 2000 was 81,000, a decrease of 
70% from a peak of approximately 280,000 in the mid-1980’s.  In addition 
to acute disease, approximately 1.25 million persons in the United States 
have chronic HBV infection. These persons are at increased risk for 
chronic liver disease, including cirrhosis and hepatocellular carcinoma, 
and they are the major reservoir of ongoing HBV transmission. 
The incidence of HBV infection differs significantly by race and 
ethnicity with the highest rates among blacks; rates are higher among 
Hispanics than non-Hispanics. Incidence also varies by age with the 
highest rates reported among persons 20-39 years of age.  Less than 5% 
of the HBV infections that occur among children are reported as cases of 
acute hepatitis B to CDC because HBV infections that occur in infants 
and children rarely produce signs or symptoms of disease. Furthermore, 
chronic HBV infection develops in approximately 90% of children infected 
at birth and 30%-60% of children infected between 1 to 5 years of age 
compared with 2%-6% of older children and adults; thus, prior to routine 
immunoprophylaxis of infants and children, cases occurring in children 
accounted for a disproportionate amount of the disease burden due to 
chronic infection. 
  In addition to infections occurring in childhood, CDC estimates that 
20,000 (95% confidence interval, 15,000 to 32,000) infants are born to 
HBsAg positive mothers each year 5. Post-exposure prophylaxis is highly 
effective in preventing transmission of HBV from mother to infant. 
However, an estimated 1000 of these infants become chronically infected 
with HBV each year because not all infected mothers are identified and 
not all infants receive appropriate post-exposure prophylaxis. Although 
perinatal HBV infections have been nationally notifiable since 1995, 
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Enhanced 
surveillance for cases 
occurring in age 
groups for which 
routine vaccination is 
recommended (i.e., 
children <18 years of 





monitor and evaluate 
the operation of 
childhood vaccination 
programs.
reported cases have not been reliable for monitoring the number of 
perinatal infections that are occurring in the United States because of a 
lack of follow-up serologic testing of infants born to infected mothers. 
Prevention strategies/recommendations
Hepatitis B vaccine has been available in the United States since 
1982. A comprehensive immunization strategy to eliminate HBV 
transmission in the United States includes 1) preventing perinatal HBV 
transmission by screening all pregnant women for HBsAg and providing 
immunoprophylaxis to infants of HBV-infected women; 2) routine 
immunization of all infants; 3) catch-up vaccination of all previously 
unvaccinated children aged <19 years, with priority for vaccination at 11 
to 12 years of age; and 4) vaccination of adolescents and adults at high 
risk for infection including persons with a history of multiple sex partners 
(>1 partner/6 months) or a sexually-transmitted disease; men who have 
sex with men; injecting drug users; incarcerated persons; household and 
sex contacts of persons with chronic HBV infection; health care and 
public safety workers who have exposure to blood in the workplace; and 
hemodialysis patients. 
Surveillance
To accomplish the goals of conducting surveillance for hepatitis B, 
multiple types of surveillance activities are needed, including surveillance 
for acute hepatitis B, surveillance for perinatal HBV infection, and 
surveillance for persons who test positive for HBsAg to identify those 
with chronic HBV infections. 
Surveillance for acute hepatitis B—newly acquired symptomatic 
infections – is needed to monitor ongoing transmission of HBV, and 
investigation of these cases to determine their characteristics and risk 
factors provides the information needed for monitoring trends in 
transmission patterns and targeting prevention activities. Enhanced 
surveillance for cases occurring in age groups for which routine 
vaccination is recommended (i.e., children <18 years of age) to determine 
their characteristics and vaccination history provides information to 
monitor and evaluate the operation of childhood vaccination programs. 
Additional information on reported cases of acute hepatitis B is useful to 
identify settings in which hepatitis B vaccine could have been offered. 
Analysis of cases of acute hepatitis B reported during 1996-1998 
indicated that more than half had previously received care in settings 
where hepatitis B vaccine is recommended (i.e. STD clinics, correctional 
facilities) 6. Furthermore, 40% of persons who report no recognized risk 
factor for infection during their exposure period reported high-risk 
characteristics or behaviors that place them in groups for which hepatitis 
B vaccine is recommended (past history of MSM activity, IDU or treatment 
for a STD). Monitoring changes in the incidence of acute disease 
provides data to assess the impact of hepatitis B vaccination programs. 
National hepatitis B disease reduction objectives for the year 2010 
include reducing the incidence of acute hepatitis B among persons <19 
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Many states currently 
have regulations 
requiring laboratories 
to report all HBsAg 
positive results to 
local health 
departments. These 
results can be used to 
identify persons with 
chronic HBV 
infection who need 
counseling and 
referral for medical 
follow-up and whose 
contacts require 
immunization. 
years of age by >99% and reducing hepatitis B incidence in adult high 
risk groups by >75% 7. The effect of routine infant and adolescent 
vaccination can already be seen in the declining rate of disease in 
persons <19 years of age. Similarly, the impact of a 1992 OSHA rule 
requiring employers to offer hepatitis B vaccine to at risk employees is 
demonstrated by vaccine coverage levels of >65% and a decrease of 
>70% in the number of cases occurring among health care workers since 
1993. In contrast, the continued high incidence among persons in other 
risk groups for which vaccination is recommended such as injection drug 
users and persons engaging in high risk sexual behaviors indicates that 
programs for reaching these populations with vaccine need to be 
developed or strengthened.
The timely identification of persons recently infected with HBV 
provides the opportunity not only to counsel the infected individual but 
also to identify susceptible contacts requiring post-exposure prophylaxis 
early enough to prevent further transmission. Fifteen to 20% of acute 
hepatitis B cases are acquired from a known infected contact and could 
have been prevented by timely pre- or post-exposure prophylaxis (JID, 
submitted). By monitoring the exposures of recently infected persons, 
surveillance for acute disease also provides the information critical for 
identifying outbreaks of hepatitis B that, while uncommon, do occur. 
Nosocomial outbreaks involving patient-to-patient transmission have 
occurred in association with a variety of transmission vehicles including 
multidose medication vials, reusable fingerstick devices, and other 
contaminated medical equipment 8, 9, 10, 11, 12. Although cases of 
provider-to-patient transmission of HBV are rare in the United States 
continued vigilance is needed to detect these cases should they occur. 
Surveillance for perinatal HBV infection is needed to evaluate the 
effectiveness of the perinatal HBV prevention program by monitoring the 
incidence of these infections and to identify HBV-infected infants for 
referral for medical management and treatment if appropriate. 
Surveillance for perinatal HBV infection depends upon the identification of 
HBV-infected mothers by screening pregnant women for HBsAg and the 
post-vaccination testing of infants born to HBV-infected mothers. Post-
vaccination testing also identifies uninfected infants who did not respond 
to vaccination and require re-vaccination because of ongoing exposure to 
infected household contacts including their mothers. 
Intensive investigation of infected infants is needed to assess and 
reduce missed opportunities for providing post-exposure 
immunoprophylaxis and to assess the frequency and risk factors for 
failure of immunoprophylaxis. Although rare, possible reasons for failure 
of immunoprophylaxis include incomplete vaccination, in utero infections, 
delayed vaccination doses, and infection with an HBV variant 13, 14, 15, 16, 17 
Surveillance for chronic HBV infection: HBsAg can be detected in virtually 
all persons with chronic HBV infection. Many states currently have 
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regulations requiring laboratories to report all HBsAg positive results to 
local health departments. These results can be used to identify persons 
with chronic HBV infection who need counseling and referral for medical 
follow-up and whose contacts require immunization.
Determining the frequency and characteristics of persons reported 
as HBsAg-positive also describes who and where infected persons are 
being identified. Although dependent upon testing practices, this 
information can help in developing minimum estimates of infection burden 
and is useful for identifying gaps in current testing practices. Further 
investigation of chronically infected persons (or a sample of them) to 
determine why they were identified and what actions (e.g. medical 
evaluation, vaccination of contacts) resulted from being identified 
provides information to direct and evaluate prevention activities. 
Hepatitis C 
Epidemiologic characteristics
Hepatitis C virus (HCV) infection is the most common chronic 
bloodborne infection in the United States. Although the annual number of 
new infections has declined since 1989 by more than 80% to 36,000 in 
2000, data from the Third National Health and Nutrition Examination 
Survey 18 conducted during 1988-1994 indicate that there are an 
estimated 3.9 million Americans who have been infected with HCV. 
Approximately 75% of these persons are chronically infected and may not 
be aware of their infection because they are not clinically ill. These 
persons serve as a source of transmission to others and are at risk for 
chronic liver disease or other HCV-related chronic diseases. 
HCV infection occurs among persons of all ages, but the highest 
incidence of acute hepatitis C is found among persons 20-39 years. 
African Americans and whites have similar incidence rates of acute 
disease with higher rates in persons of Hispanic ethnicity. 
Prevention strategies
With no effective vaccine or post-exposure prophylaxis, reducing 
the burden of HCV infection and HCV-related disease in the United 
States requires implementation of primary prevention activities to reduce 
the risk of contracting the infection and secondary prevention activities to 
reduce the risk of liver disease and other HCV-related chronic diseases 
among HCV-infected persons 19. 
Surveillance
Hepatitis C surveillance is a critical component of a comprehensive 
strategy to prevent and control HCV infection and HCV-related chronic 
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liver disease. To accomplish the goals of hepatitis C surveillance, 
activities are needed to identify persons with acute hepatitis C, as well as 
persons with chronic HCV infection. 
Surveillance for acute hepatitis C –newly acquired symptomatic 
infection- is needed to monitor ongoing transmission of HCV, and 
investigation of these cases to determine their characteristics and risk 
factors provides the best information for monitoring trends in transmission 
patterns. The collection of this information for reported cases is useful for 
characterizing groups at risk of infection and targeting prevention 
activities. Monitoring changes in acute disease incidence and in the risk 
factors for infection can be used to assess the effectiveness of prevention 
programs. 
By monitoring the exposures of recently infected persons, 
surveillance for acute hepatitis C also provides the information needed to 
detect outbreaks that, while uncommon, do occur. Although rarely 
reported in the United States except in the chronic hemodialysis setting, 
nosocomial outbreaks of HCV involving patient-to-patient transmission 
can occur if infection control techniques or disinfection procedures are 
inadequate and contaminated equipment is shared among patients. The 
risk of HCV transmission from an infected health care worker to patients 
appears to be very low but vigilance is needed to detect these cases 
should they occur. 
Conducting surveillance for acute hepatitis C on a nationwide 
basis has been difficult because a) no serologic marker for acute infection 
is available; b) cases are usually reported on the basis of a positive 
laboratory report and most health departments do not have the resources 
to conduct investigations to determine if these reports represent acute 
infection, chronic infection, repeated testing of a person who was 
previously reported, or a false-positive result; and c) it can be difficult to 
differentiate acute infection from exacerbation of chronic infection based 
on clinical features of disease. Thus, the cases reported as acute 
hepatitis C to the National Notifiable Disease Surveillance System have 
been unreliable to date. Instead acute disease incidence and 
transmission patterns have been monitored using reported cases from 
CDC’s Sentinel Counties Study of Acute Viral Hepatitis, in which all 
patients with signs and symptoms of viral hepatitis are investigated to 
ascertain cases of acute hepatitis C. 
However, reliable state-specific data are needed to direct and 
evaluate hepatitis C prevention and control programs. In addition to 
expanding the use of strategies such as sentinel surveillance or serial 
serologic surveys to address local needs for hepatitis C surveillance data, 
the implementation of methods that facilitate the management and 
evaluation of case reports of suspected hepatitis C can enhance the 
capacity of state or local health departments to conduct surveillance for 
acute hepatitis C. For example, the revision of the case definition for 
acute hepatitis C to include a higher ALT threshold provided a more 
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efficient and specific criterion to determine which reports require further 
investigation to distinguish anti-HCV positive individuals with acute 
disease from those with remote or chronic infection. 
Surveillance for HCV-Infection.  Many states currently have 
regulations requiring laboratories to report all anti-HCV positive results to 
local health departments. Although limitations exist to the use of anti-
HCV positive laboratory reports to conduct surveillance for HCV infection, 
these reports can be an important source from which state and local 
health departments can identify HCV-infected persons who need 
counseling and medical follow-up. 
Determining the frequency and characteristics of persons reported 
as anti-HCV-positive also describes who and where infected persons are 
being identified. Although dependent upon testing practices, this 
information can help in developing minimum estimates of infection burden 
and is useful for identifying gaps in current testing practices. Further 
investigation of chronically infected persons (or a sample of them) to 
determine why they were identified and what actions (e.g. medical 
evaluation) resulted from being identified provides information to direct 
and evaluate prevention activities. 
Non-ABC Hepatitis
HAV, HBV and HCV are the etiologic agents of >95 % of acute viral 
hepatitis in the United States. However, a small percentage of persons 
with signs and symptoms typical of acute viral hepatitis do not have 
serologic markers of infection with these viruses, and may be infected 
with other viruses. Hepatitis D (delta) virus (HDV) is an incomplete virus 
that requires the helper function of HBV to replicate. HDV can be 
acquired either as a coinfection with HBV or as a superinfection in 
persons with chronic HBV infection. The incidence of delta hepatitis 
cannot be directly calculated from national surveillance data because this 
disease is not reportable in the United States; however, in prevalence 
studies among patients with acute hepatitis B, 1.5-7.2% had serologic 
evidence of HBV-HDV coinfection 20. 
Hepatitis E is rare in the United States and most reported cases 
have been associated with travel to HEV-endemic countries 21, 22. 
However, several cases of acute hepatitis E have been reported in 
persons with no recent history of travel outside the United States 23, 24 and 
HEV infection should be considered in patients with non-ABC hepatitis. 
Additional candidate hepatitis viruses that have been isolated from 
patients with posttransfusion hepatitis include hepatitis G virus (also 
called GB virus C), TTV, and SENV 25, 26, 27, 28; however, none of these 
viruses has been demonstrated to be a cause of acute or chronic 
hepatitis 27, 29. 
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The clinical features 
of acute disease 
caused by hepatitis 
viruses are similar. 
Thus, serologic 
testing is necessary to 
establish a diagnosis 
in persons with 
jaundice or other 
signs and/or 
symptoms of acute 
hepatitis. 
GENERAL SURVEILLANCE GUIDELINES 
Case Ascertainment 
Methods to improve the timeliness and completeness of reporting include 
a) implementing laboratory reporting laws, b) ensuring that all patients 
who have signs and symptoms of acute viral hepatitis are appropriately 
tested and reported; and c) ensuring that all patients with chronic 
hepatitis, or who have risk factors for HBV or HCV infection are 
appropriately tested and reported if positive. 
Laboratory reporting rules.  All states should implement rules or 
regulations requiring laboratories to promptly report test results positive 
for any of the following serologic markers of acute or chronic hepatitis: 
• IgM antibody to HAV (IgM anti-HAV); 
• Hepatitis B surface antigen (HBsAg); 
• IgM antibody to hepatitis B core antigen (IgM anti-HBc); and 
• Antibody to HCV (anti-HCV). 
Computerized data systems are maintained by many clinical 
laboratories. The establishment of information management systems for 
receiving data electronically from laboratories can facilitate surveillance 
for viral hepatitis by increasing timeliness and completeness of case 
identification. State regulations for laboratory reporting of serologic 
markers of viral hepatitis should include requirements to report available 
information which could facilitate case identification and investigation, 
including contact information for the patient and for the patient’s 
physician. Reports of positive test results should also include the results 
for other serologic markers of viral hepatitis that were evaluated on the 
same individual, and serum aminotransferase (e.g. ALT) levels, if 
available. In addition, pregnancy status should be reported if testing was 
done as part of a prenatal test panel. 
Testing of patients with signs and/or symptoms of acute viral 
hepatitis. The clinical features of acute disease caused by hepatitis 
viruses are similar. Thus, serologic testing is necessary to establish a 
diagnosis in persons with jaundice or other signs and/or symptoms of 
acute hepatitis (e.g., anorexia, nausea, malaise, vomiting, dark urine, clay 
colored or light stools, and abdominal pain). Appropriate diagnostic 
testing of such patients is crucial to ensure complete case ascertainment. 
To facilitate accurate testing, laboratories, managed care organizations 
and payors should encourage implementation and use of standardized 
diagnostic panels for testing patients with signs and symptoms of acute 
hepatitis which should include all of the serologic markers that are 
included in state laboratory reporting requirements (e.g., IgM anti-HAV, 
HBsAg, IgM anti-HBc, and anti-HCV). In addition, educational efforts 
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Most persons with 
chronic HBV or HCV 
infection are 
asymptomatic. Thus, 
testing programs for 
persons with risk 
factors for infection 
and/or elevated liver 
enzymes (e.g., ALT, 
AST) are required to 
identify chronically 
infected persons. 
organizations to increase awareness of appropriate testing algorithms 
and reporting laws among clinicians. 
Testing of patients with chronic hepatitis, or risk factors for chronic 
HBV or HCV infection. Most persons with chronic HBV or HCV infection 
are asymptomatic. Thus, testing programs for persons with risk factors for 
infection and/or elevated liver enzymes (e.g., ALT, AST) are required to 
identify chronically infected persons. Routine screening of pregnant 
women for HBsAg is done to identify infants of infected women who 
require post-exposure prophylaxis. High risk populations for chronic 
HBV infection (e.g., STD and drug treatment patients, inmates of 
correctional facilities, immigrants from countries with a HBsAg prevalence 
>2%) might benefit from routine HBsAg testing, but the feasibility and cost 
effectiveness of such testing in various clinical settings has not been 
determined. Recommendations have been developed for routine anti-
HCV testing for persons at high risk of HCV infection (i.e., persons who 
have ever injected illegal drugs, persons who received a blood 
transfusion or organ transplant before July 1992, persons ever on chronic 
hemodialysis, persons who received clotting factor concentrates made 
before 1987, persons with abnormal liver enzyme levels) 30. 
The specificity of HBsAg or anti-HCV testing is high when used to 
evaluate persons with signs or symptoms of hepatitis. However, as with 
any test, the positive predictive value of these tests when used to screen 
asymptomatic persons depends on the prevalence of the condition 
among the persons being tested, and the likelihood of a false-positive test 
result increases when the tests are used in low-risk populations. 
Confirmation of a positive test result for HBsAg or anti-HCV by an 
additional more specific assay is needed to rule out a false-positive result, 
especially in persons with no identified risk factor for infection. The 
presence of other serologic markers of HBV infection (i.e. total anti-HBc 
or IgM anti-HBc) can be used to evaluate the likelihood that an HBsAg 
positive test result is a true positive but isolated HBsAg positive test 
results should be verified by a confirmatory assay (e.g. neutralization 
assay). Anti-HCV positive results by enzyme immunoassay (EIA) should 
be verified by a supplemental antibody assay (e.g., RIBA™). If 
supplemental test results are not available, a positive EIA test can also be 
confirmed by calculating the signal to cutoff ratio (S/CO) for the specimen. 
If the S/CO is $3.8, the likelihood that the specimen would be positive by 
supplemental assay is >95%. Detection of HCV RNA by RT-PCR 
verifies HCV infection, but the absence of detectable RNA in a single 
serum specimen does not exclude the possibility of HCV infection. 
Case Reporting
Data elements 
The collection of a minimum set of standardized data elements 
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Confirmation of a 
positive test result for 
HBsAg or anti-HCV 
by an additional more 
specific assay is 
needed to rule out a 
false-positive result, 
especially in persons 
with no identified risk 
factor for infection 
(Table I) on all reported cases of viral hepatitis ensures that information 
collected can be effectively used at the local, state and national level. 
These minimum data elements should conform wherever possible to the 
definitions and formats specified for NEDSS. In addition to locators (e.g., 
state, county of report) and demographic descriptors (e.g., age, race, 
ethnicity, sex), the following information, required for classifying the case 
as acute or chronic and for determining appropriate follow-up should be 
reported for every case: 
•	 Presence of symptoms consistent with acute hepatitis and the 
date of onset for those symptoms 
•	 Presence of jaundice 
•	 Results and date of serum aminotransferase testing, if available. 
•	 Serologic test results for any markers of viral hepatitis (see Case 
Ascertainment) 
Unique Identifiers. Patient name and other identifying information (e.g. 
birthdate/social security number) are typically maintained as part of state 
surveillance databases. A unique identifier is essential for appropriate 
patient follow-up, distinguishes newly identified cases from previously 
reported individuals and allows linkage to related health-care data. 
Efforts are underway by CDC and its’ public health partners to develop a 
unique identifier composed of standardized data elements that are used 
throughout the health-care and public health sectors. Policies for ensuring 
patient privacy and security of data should be in place for any system 
maintaining unique patient identifiers. 
In addition to these core elements, information including recent 
exposures should be collected and reported as part of the recommended 
case investigation of cases of acute viral hepatitis or perinatal HBV 
infection. The information to be collected and reported for investigations 
of different types of viral hepatitis are described in the virus specific 
guidelines below. Recommendations regarding the types of information 
that might be collected in a chronic infection database also are included in 
the disease specific sections below; however, further evaluation is 
needed to determine the types of information that will be most useful. 
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Table I: Information elements to be collected for case reports of viral hepatitis 
Information Collected	 Comments 
Locator Information
•	 State, county, ZIP code Core variables (NEDSS standards) 
Demographic Information
•	 Date of birth, age, sex, race, ethnicity Core variables (NEDSS standards) 
Clinical Data 
•	 Date of illness onset First sign or symptom of hepatitis 
•	 Presence of symptoms of acute Verifies case definition 
hepatitis 
•	 Presence of jaundice Verifies case definition 
•	 ALT level Verifies case definition 
•	 Hospitalization for hepatitis If yes, verify dates of hospitalization 
•	 Death from hepatitis If yes, review death certificate and medical records 
to rule out other potential causes of death and to 
confirm acute liver failure as cause of death 
Diagnostic Testing Results 
•	 IgM anti-HAV, HBsAg, IgM anti-HBc, Verifies case definition. Determine all results 
anti-HCV, anti-HDV 	 (positive and negative). HBsAg and anti-HCV 
positive test results require confirmation by an 
additional more specific assay or for anti-HCV, a 
S/CO ratio $ 3.8. 
•	 Date of diagnosis Date of test result confirming infection 
Other 
•	 Pregnancy Status If pregnant, infants of HBV or HCV infected women 
should be tested for infection (see disease specific 
guidelines) 
•	 Origin of report Site requesting viral hepatitis testing 
Reporting cases to CDC 
With the implementation of NEDSS, which will include standards 
for electronic transfer of data, all reporting of viral hepatitis case data, 
including risk factor information, will occur electronically. States that 
currently transmit VHSP data electronically via NETSS should discontinue 
paper-based reporting. CDC is committed to working with those states 
that rely on paper-based reporting to overcome barriers to electronic 
reporting of hepatitis surveillance data. 
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Computerized 
databases of HBsAg 
positive and anti-
HCV positive persons 






with HBV or HCV. 
Databases of persons chronically infected with HBV or HCV 
Computerized databases of HBsAg positive and anti-HCV positive 
persons can facilitate the notification, counseling and medical 
management of persons chronically infected with HBV or HCV. These 
databases can be used to: 
•	 distinguish newly reported cases of infection from previously identified 
cases; 
•	 facilitate and track the follow-up of chronically infected persons; and 
•	 provide local, state, and national estimates of the proportion of 
persons with chronic HBV or HCV infection who have been identified. 
The specific information elements to be maintained in a database of 
chronically infected persons will depend upon the objectives of 
establishing the database and the feasibility of collecting that information. 
At a minimum, sufficient information should be collected to distinguish 
newly identified persons from previously reported individuals including 
information to establish a unique identifier (e.g. name, race, date of birth) 
and serologic test results to confirm chronic infection with HBV or HCV. 
Information about the clinical characteristics of the individual (e.g. 
presence of symptoms consistent with acute viral hepatitis, date of 
symptom onset, results of liver enzyme testing) and why they were 
identified can help to distinguish persons with chronic infection from those 
with acute disease. The collection of the minimum demographic 
information that is required for reporting of acute cases is also 
recommended for cases of chronic infection as these data can be used to 
describe the population of infected persons that has been identified, 
information useful for allocating public health resources and directing and 
evaluating prevention programs. The collection of additional information 
for a sample of persons in these databases can be useful to further 
characterize the infected population (e.g. past exposures or risk factors) 
or to assess the impact of public health follow-up of these persons (e.g. 
did they receive medical evaluation, did their susceptible contacts receive 
appropriate follow-up). The recommended information to be collected in 
databases of persons with chronic HBV or HCV infection is included in 
the disease specific sections below. 
When any type of database is established, the confidentiality of 
individual identifying information should be ensured according to 
applicable laws and regulations. Guidelines that clarify how and when 
line-listed data with or without personal identifiers are transmitted and 
used can facilitate the protection of confidential data. 
Methods for accomplishing the follow-up of persons identified in 
chronic infection databases include contacting health care practitioners 
and/or patients individually by telephone, mail or in person. Mechanisms 
such as automated systems for the mailing of follow-up educational 
materials might be useful. Such systems require relatively few health 
department resources and involve little or no interaction with patients or 
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their health care practitioner; however, the effectiveness of such systems 
should be evaluated. Effective mechanisms for delivering follow-up to 
mobile and hard-to-reach individuals such as injection drug users need to 
be identified. 
Monitoring the Quality of Surveillance Data  
Periodic, regular evaluations of surveillance data for quality, 
completeness, and timeliness are essential to identify specific aspects of 
surveillance and case investigation that need improvement. The 
completeness of surveillance data is assessed by determining the 
frequency with which individual data elements are reported with non-
missing data. The quality or validity of the data is measured by the 
proportion of each data element that is reported with a correct or valid 
answer. Timeliness of surveillance data can be measured by determining 
the average length of time in days required for each of the steps in the 
surveillance process. 
The use of standardized indicators to assess the completeness (e.g. 
proportion of cases that are reported with risk factor information) or 
timeliness (e.g. time between date of diagnostic testing and date reported 
to health department) of surveillance data will allow more accurate 
interpretation and comparison of data reported at different times or by 
different sources. The development of data quality indicators to measure 
the completeness of case-investigation and follow-up activities (e.g., 
proportion of at-risk contacts immunized) also might be useful. 
Data Analysis and Dissemination 
Periodic summaries of analyzed surveillance data that are 
accompanied by a concise interpretation can be useful to a variety of 
audiences including public health decision makers, clinical case 
reporters, and other health professionals. Health department should 
consider developing specialized communications for dissemination of 
annual reports of case rates analyzed by person, place and time to 
different audiences. These communications might also include: reports to 
data providers identifying providers’ specific contribution to surveillance 
efforts, newsletters or bulletins providing concise data interpretation and 
advice to clinicians and laboratory directors, and press release/reports for 
general public releases. In addition to dissemination via printed media, 
other dissemination mechanisms such as the internet should be explored 
In addition to summarized data, line listed data should be provided 
to local health departments to ensure complete and accurate description 
of identified cases and to highlight those cases that require further follow-
up. The regular (at least quarterly) provision of summarized state specific 
surveillance data by CDC can be useful to state and local health 
departments in monitoring the reporting of cases to CDC and in providing 
feedback to local health departments and other public health partners. 
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An acute illness with 
•	 discrete onset of symptoms (e.g. fatigue, abdominal pain, loss 
of appetite, intermittent nausea, vomiting), and 
•	 jaundice or elevated serum aminotransferase levels 
Laboratory criteria 
•	 IgM antibody to hepatitis A virus (anti-HAV) positive 
Case Classification 
•	 Confirmed. A case that meets the clinical case definition and 
is laboratory confirmed or a case that meets the clinical case 
definition and occurs in a person who has an epidemiologic 
link with a person who has laboratory-confirmed hepatitis A 
(i.e., household or sexual contact with an infected person 
during the 15-50 days before the onset of symptoms). 
*This case definition was approved by CSTE in September, 1996. 31 
To date, asymptomatic individuals who are IgM anti-HAV positive 
have not been included as reportable cases. However, these cases do 
represent incident infections and it is expected that as rates of acute 
disease continue to decline, the case definition will be expanded to 
include newly infected individuals identified on the basis of laboratory 
results alone. When the case definition is expanded to include 
asymptomatic HAV infections, these cases will need to be distinguished 
from symptomatic cases to ensure accurate interpretation of surveillance 
data. 
Case Ascertainment 
The primary methods to ascertain suspected acute hepatitis A cases are 
•	 Laboratory reporting of all persons who test IgM anti-HAV positive to 
state and/or local health departments; and 
•	 Reporting by health care practitioners of persons with symptoms of 
acute hepatitis who are IgM anti-HAV positive. Persons reported as 
suspected cases of viral hepatitis on the basis of clinical criteria 
alone should be followed up to ensure that appropriate diagnostic 
testing for acute viral hepatitis is done. 
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Case Investigation
Confirmed or suspected cases of acute hepatitis A should be reported 
and investigated as soon as possible after the case is identified to ensure 
adequate time to implement preventive measures, including the provision 
of post-exposure prophylaxis to contacts. To report a case as confirmed, 
it should be verified that the case meets both the serologic and clinical 
criteria of the case definition. The components of a case investigation 
should include: 
•	 Clinical features.  Determine date of illness onset, whether jaundice 
was present and results of testing for aminotransferase levels. 
•	 Serologic test results. For suspected cases, confirmation by IgM 
anti-HAV testing is ideal but if not done, a potential case of acute 
hepatitis A can be reported as confirmed if the person has an 
epidemiologic link. 
•	 Risk factors for infection.  (Table II) All confirmed cases of acute 
hepatitis A should be interviewed to identify a potential source or risk 
factor for infection during the 2-6 weeks prior to illness onset. 
Because IgM antibodies persist for up to 6 months after infection, it is 
not possible to define the appropriate exposure period for 
asymptomatic IgM anti-HAV positive persons. Therefore, risk 
histories for these persons may be unreliable for determining a source 
of infection. 
•	 Identification of contacts requiring post exposure prophylaxis. 
Immunoprophylaxis with immune globulin (IG) should be provided to 
persons recently exposed to a person with acute hepatitis A including 
close personal contacts and others in selected settings according to 
existing recommendations of the Advisory Committee on 
Immunization Practices32. IG should be given as soon as possible but 
not >2 weeks after the last exposure. Post-exposure prophylaxis is 
not recommended for contacts of persons with asymptomatic HAV 
infection because the period of exposure is unknown. 
Reporting to CDC
Case reports of acute hepatitis A should be transmitted weekly by 
state health departments to CDC via NETSS. Symptomatic cases 
need to be distinguished from asymptomatic cases to accurately 
assess changes in incidence. See Appendix X for CDC hepatitis A 
case report form.
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Table II. Components of Acute Hepatitis A Case Investigations 
Information Collected
 
Risk factors (2-6 weeks prior to illness onset) 

•	 Close contact with a person w/confirmed 
or suspected acute hepatitis A 
•	 Employment or attendance of nursery, 
day care center or preschool 
•	 Household contact of a child or employee 
in a nursery, day care center or preschool 
•	 Travel outside of the United States or 
Canada 
•	 Illicit drug use 
Comments/Action
If yes, type of contact (sexual/household). 
Evaluate missed opportunities to receive 
immunoprophylaxis 
If yes, notify and investigate facility to 
determine if others are at risk for transmission 
If yes, where and how long? 
If yes, notify contacts of need for post-exposure 
prophylaxis 
If yes, notify contacts of need for post-exposure •	 No. of male sex partners 
prophylaxis•	 No. of female sex partners 
Detection and prevention of common source 
outbreaks 
•	 Employment as a foodhandler 
•	 Part of recognized common-source 
foodborne outbreak 
Vaccination history
•	 Hepatitis A vaccination status 
Results of case investigation and follow-up  
•	 Date reported to health department 
responsible for case investigation 
•	 Date case investigation initiated 
•	 At-risk contacts identified 
Missed Opportunities for 
Prevention/Vaccination 
•	 Household or sex contact of person with 
acute hepatitis A 
•	 Sought medical care prior to foreign 
travel 
•	 Ever in treatment for illicit drug use 
•	 Child living in area/state where routine 
childhood vaccination is recommended 
If yes, notify and investigate food handler and 
establishment 
Enhance case finding among persons eating at 
establishment 
If yes, determine if other cases linked to same 
source and report to CDC foodborne outbreak 
surveillance system 
If vaccinated, number of vaccine doses, date(s) 
of vaccination 
Date of first contact with patient and/or health 
care practitioner 
Specify type of contact and whether post-
exposure prophylaxis was received 
If yes, notify health care practitioner and assess 
barrier(s) to timely administration of IG 
If yes, notify health care practitioner and assess 
barrier(s) to timely administration of pre-
exposure prophylaxis (hepA vaccine and/or IG) 
If yes, determine date of most recent treatment, 
notify facility, and assess barrier(s) to receiving 
HepA vaccine 
If yes, identify child’s source of health care and 
assess reason(s) for failure to receive HepA 
vaccine.
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Uses of Surveillance Data 
Monitoring trends in disease incidence and determining risk factors 
for infection. Hepatitis A surveillance data should be analyzed at weekly 
intervals by time, place and person to monitor disease incidence. Cases 
reported in adults provide a valid measure of trends in incidence and the 
overall burden of disease in those age groups. Because most children 
with HAV infection are asymptomatic, reported cases represent only a 
small proportion of the overall burden of HAV infection in young age 
groups. Nevertheless, trends in the incidence of cases reported in 
children do reflect changes in the frequency of HAV transmission among 
children and can be used to estimate the impact of prevention strategies. 
The proportion of cases reporting specific risk factors should be 
determined to monitor disease transmission patterns. 
Identifying community-wide epidemics. Significant increases in 
hepatitis A incidence can indicate that a community-wide epidemic is 
developing and requires further investigation. Surveillance data should be 
analyzed to determine the areas (e.g., rates by county or zipcode) and 
groups (e.g., age-specific incidence rates and frequencies of reported risk 
factors ) affected. 
Identifying common-source outbreaks. The identification of clustering 
of hepatitis A cases should prompt an investigation to determine if a 
common-source outbreak is occurring. This investigation should include 
collection of additional information from reported cases regarding 
potential common exposures (e.g., restaurants, community gatherings, 
child day care centers) and enhancement of prospective surveillance to 
identify additional cases that might be associated with a common source 
of transmission. 
Amplification and sequencing of viral isolates using nucleic acid 
based methods can help to identify cases that might share a common 
source. Therefore, when investigating a possible common source 
outbreak, efforts should be made to collect sera from cases for possible 
sequence analysis. Public health professionals who need information 
regarding use of nucleic acid based methods for the investigation of 
hepatitis A outbreaks can contact CDC’s Division of Viral Hepatitis, 
National Center for Infectious Diseases at (404) 371-5910. 
Assessing missed opportunities for prevention. Case-patients whose 
source for infection was reported as household or sexual contact with a 
suspected or confirmed hepatitis A case should be investigated to 
determine if the case-patient received post-exposure prophylaxis when 
the source case was identified. The health care practitioners for these 
persons should be contacted to determine why the patient did not receive 
timely post-exposure prophylaxis (e.g., late identification of the source 
case or of the contact) so potential barriers to administering post-
exposure prophylaxis to patients at risk of hepatitis A can be identified 
and resolved. 
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Missed opportunities for vaccination should be assessed among 
cases occurring in persons for whom hepatitis A vaccination is 
recommended (e.g., adults in high risk groups such as MSM, and illicit 
drug users, or children in selected high rate states/communities) by 
inquiring about their history of previous contact with health care 
practitioners or other settings in which vaccination could have been given 
(e.g., drug treatment centers, STD clinics). These facilities and health 
care practitioners should be contacted to determine why the case-patient 
did not receive hepatitis A vaccine so potential barriers to vaccinating 
patients at risk of hepatitis A can be identified and resolved. 
Assessing the impact of vaccination programs. Age-specific 
hepatitis A rates for the target groups and the community as a whole can 
be compared to historical rates for the same age groups to assess the 
impact of routine vaccination programs. 
Acute Hepatitis B 
Case Definition (*)
Clinical criteria
An acute illness with: 
•	 discrete onset of symptoms (e.g. fatigue, abdominal pain, loss 
of appetite, intermittent nausea, vomiting), and 
•	 jaundice or elevated serum aminotransferase levels 
Laboratory criteria
•	 IgM antibody to hepatitis B core antigen (anti-HBc) positive or
Hepatitis B surface antigen (HBsAg) positive 
•	 IgM anti-HAV negative (if done) 
Case classification 
•	 Confirmed. A case that meets the clinical criteria and is 
laboratory confirmed 
To date, asymptomatic individuals who are IgM anti-HBc positive 
have not been included as reportable cases. However, it is expected that 
as rates of acute disease continue to decline, the case definition will be 
expanded to include newly infected individuals identified on the basis of 
laboratory results alone. In expanding surveillance to include 
asymptomatic HBV infections, these cases will need to be distinguished 
from symptomatic cases to ensure accurate interpretation of surveillance 
data. 
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Case Ascertainment 
The primary methods to ascertain suspected acute hepatitis B cases are: 
•	 Laboratory reporting of all IgM anti-HBc positive and HBsAg positive 
test results to state and/or local health departments; 
•	 Reporting by health care practitioners of persons with confirmed acute 
hepatitis B. Follow-up with providers reporting persons testing 
HBsAg-positive who have signs and/or symptoms of acute viral 
hepatitis to ensure testing for IgM anti-HBc;
•	 Follow-up with providers reporting persons as suspected cases of 
acute viral hepatitis on the basis of clinical criteria alone to ensure 
appropriate diagnostic testing for acute viral hepatitis. 
Case Investigation
Confirmed and suspected cases of acute hepatitis B should be reported 
and investigated as soon as possible after the case is identified to ensure 
adequate time to implement preventive measures including post-
exposure prophylaxis of contacts. To report a case as confirmed, it 
should be verified that the case meets both the serologic and clinical 
criteria of the case definition. The components of a case investigation 
should include: 
•	 Clinical features. Determine date of illness onset, whether jaundice 
was present and results of testing for elevated aminotransferase 
levels. 
•	 Serologic test results. Serologic confirmation of acute hepatitis B 
requires a positive IgM anti-HBc test result. Individuals meeting the 
clinical criteria who test positive for HBsAg but who were not tested 
for IgM anti-HBc should be classified as suspected cases. 
•	 Risk factors for infection. (Table III) All confirmed or suspected 
cases of acute hepatitis B should be interviewed to identify a source 
or risk factor(s) for infection during the 6 weeks to 6 months prior to 
illness onset. Because IgM antibodies persist for up to 6 months after 
infection, it is not possible to define the appropriate exposure period 
for asymptomatic IgM anti-HAV positive persons. Therefore, risk 
histories for these persons may be likely to be unreliable for 
determining a source of infection. 
•	 Vaccination history. Obtain a complete history of all doses of 
hepatitis B vaccine received including dates of vaccination and the 
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•	 Identification of contacts who require post exposure prophylaxis. 
Immunoprophylaxis following exposure to a person with acute 
hepatitis B (HBsAg positive) should be provided according to existing 
recommendations of the Advisory Committee on Immunization 
Practices 33. At-risk contacts requiring post-exposure prophylaxis 
include infants whose primary caretaker has acute hepatitis B, sexual 
partners, and other contacts who have had a blood exposure to the 
index patient (e.g., needle sharing contacts of injection drug users, 
non-sexual household contacts who may have had inapparent 
exposure to the blood of the index patient through exposures such as 
sharing toothbrushes or razors). The vaccination status of children 
and adolescents in the household of a person with acute hepatitis B 
should be assessed to ensure that they receive vaccine if not 
previously vaccinated. 
•	 Referral for medical evaluation.  Persons with acute hepatitis B 
should be evaluated for the development of chronic infection. The 
detection of HBsAg >6 months after illness onset indicates the 
presence of chronic infection. 
Reporting to CDC 
Case reports of acute hepatitis B should be transmitted weekly by 
state health departments to CDC via NETSS. In reporting, 
symptomatic cases need to be distinguished from asymptomatic cases 
to accurately assess changes in incidence. See Appendix X for CDC 
Hepatitis B case report form. 
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Table III. Components of Acute Hepatitis B Case Investigations 
Information Collected
Risk factors (6 wks-6 mo prior to illness 
onset) 
•	 Contact with a person w/confirmed or 
suspected HBV infection 
•	 Employment involving contact with human 
blood 
•	 Receipt of blood transfusion or blood 
products 
•	 Dialysis or kidney transplant patient 
•	 Injecting drug use 
•	 Number of different male sex partners 
•	 Number of different female sex partners 
•	 Hospitalization and/or surgery
•	 Intravenous infusions or injections received 
in outpatient settings 
•	 Residence in a long term care facility (e.g. 
nursing home) 
•	 Dental work/oral surgery
•	 Acupuncture/tattooing/body piercing 
•	 Puncture with a needle or other object 
contaminated w/blood 
Vaccination History
•	 Hepatitis B vaccination status 
Results of Case Investigation and Follow-up
•	 Date reported to health department 
responsible for case investigation 
•	 Date case investigation initiated 
•	 At risk contacts identified
•	 At risk contacts initiating prophylaxis 
•	 Date referred for medical evaluation 
Missed Opportunities for Hepatitis B 
Vaccination
•	 Household or sex contact of HBV-infected 
person
•	 Ever in correctional facility




• Ever in treatment for injecting drug use 
Comments/Action
Type of contact (sexual, household, casual) 
Degree of blood contact (several times weekly/infrequent) 
Product(s) administered, date(s) received 
Notify and investigate facility; assess barriers to vaccination 
Notify at risk contacts of need for hepatitis B  
vaccination -- (and HBIG, if it can be administered 
within 14 days of last contact) 
Determine if additional cases are linked to same facility; assess 
need for investigation for a nosococomial source of infection 
Determine post-exposure prophylaxis history: date(s) of HBIG 
administration, date(s) of vaccination 
If vaccinated, number of vaccine doses, date(s) of vaccination, 
and post-vaccination test results (if available) 
Date of first contact with patient and/or health care practitioner 
Sexual contacts, household contacts, and 
needle-sharing contacts 
Need to assure completion of 3-dose HepB vaccine series 
Evaluate for development of chronic infection including testing 
for HBsAg >6 months after illness onset 
Notify health care practitioner and assess barrier(s) to providing 
HepB vaccine 
Determine date of most recent incarceration, notify facility and 
assess barrier(s) to providing HepB vaccine 
If yes, determine date of most recent treatment, notify facility,
and assess barrier(s) to providing HepB vaccine 
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Uses of Surveillance Data 
Identifying outbreaks. Identification of any of the following risk factors 
among persons with acute hepatitis B should prompt an investigation to 
determine if additional cases are associated with a common source of 
transmission: 
Receipt of blood or blood products. When cases are identified in 
persons who received a blood transfusion during the incubation period, 
the transfusion service and the blood collection establishment should be 
notified. For patients who have no other recognized risk factors for 
infection, the blood collection establishment should identify and retest the 
donor(s) for evidence of HBV infection (HBsAg, anti-HBc). For persons 
who received plasma-derived products during the incubation period, the 
specific product name and lot number should be obtained. 
 Hemodialysis.  The patient’s dialysis unit should be contacted to 
determine if additional cases have been detected. Current policies of the 
unit should be determined regarding vaccination and routine serologic 
testing of patients as well as infection control practices. The unit should 
be provided with appropriate recommendations to prevent transmission of 
HBV and other bloodborne pathogens in the facility34. 
Hospitalization, surgery, other medical or dental procedures. 
Additional information should be obtained regarding the specific medical 
care provider(s) and setting (e.g., hospital, clinic) involved. The 
occurrence of at least two cases associated with the same medical care 
provider or setting or one case with no other recognized risk factors for 
infection should prompt an investigation to determine if there is a 
nosocomial source of infection. 
Monitoring trends in disease incidence and determining risk factors 
for infection. Acute hepatitis B surveillance data should be analyzed at 
regular intervals (e.g., weekly) by time, place, and person to monitor 
disease incidence. The proportion of cases with specific risk factors
should be determined to monitor disease transmission patterns and to 
identify high risk groups that need to be targeted by vaccination 
programs. 
Assessing missed opportunities for prevention. Case-patients whose 
source for infection was reported as household or sexual contact with a 
person with acute or chronic HBV infection should be investigated to 
determine if the case-patient should have been immunized when the 
source case was identified. The health care practitioners for these 
persons should be contacted to determine why the case-patient did not 
receive hepatitis B vaccine so barriers to vaccinating at-risk contacts of 
identified cases can be identified and resolved. 
Missed opportunities for pre-exposure vaccination should be 
assessed among cases of acute hepatitis B occurring in persons for 
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whom hepatitis B vaccination is recommended (e.g.,MSM, injecting drug 
users) by inquiring about their history of previous contact with health care 
practitioners or other settings in which vaccination could have been given 
(e.g., STD clinics, correctional facilities, drug treatment centers). These 
facilities/health care practitioners should be contacted to determine why 
the case-patient did not receive hepatitis B vaccine so barriers to 
vaccinating persons belonging to groups at increased risk of HBV 
infection can be identified and resolved. Missed opportunities for 
vaccination should also be assessed among cases occurring in children 
less than 18 years of age to determine the frequency and characteristics 
of these cases so that the effectiveness of routine childhood vaccination 
programs can be monitored and any barriers to vaccinating children can 
be identified and resolved. 
Assessing the frequency and causes of immunization failure. The 
frequency of cases occurring in vaccinated persons should be determined 
to monitor the efficacy of vaccination and to detect possible cases of 
vaccine failure. Additional investigation is needed to identify causes for 
these potential breakthrough infections (e.g., waning of vaccine induced 
immunity, infection with viral variants). Health care professionals who 
need information regarding investigation of these cases can contact 
CDC’s Division of Viral Hepatitis, National Center for Infectious Diseases 
at (404) 371 5910. 
Perinatal HBV Infection 
Case Definition (*)
Clinical description 
Perinatal HBV infection in the newborn can range from asymptomatic to 
fulminant hepatitis. 
Laboratory criteria 
Hepatitis B surface antigen (HBsAg) positive 
Case classification 
HBsAg positivity in any infant >1-24 months old who was born in the 
United States or in U.S. territories to an HBsAg-positive mother. 
Comment: Infants born to HBsAg-positive mothers should receive 
hepatitis B immune globulin (HBIG) and the first dose of hepatitis B 
vaccine within 12 hours of birth, followed by the second and third doses of 
vaccine at 1 and 6 months of age, respectively. Postvaccination testing 
for HBsAg and anti-HBs (antibody to HBsAg) is recommended from 3 to 6 
months following completion of the vaccine series. If HBIG and the initial 
dose of vaccine are delayed for >1 month after birth, testing for HBsAg 
may determine if the infant is already infected. 
*This case definition was adopted by CSTE in March 1995 31. 
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Case Ascertainment 
Virtually all infants who are infected with HBV are asymptomatic. 
The primary method for identifying such infants is to test pregnant women 
for HBsAg and test the infants born to infected women for HBsAg at 9-15 
months of age. 
To facilitate identification of HBV-infected infants: 
•	 consider laws or regulations to require prenatal HBsAg screening of 
all pregnant women; 
•	 ensure that all birthing hospitals have appropriate written standing 
orders and/or administrative procedures for determining the HBsAg 
status of all pregnant women during each pregnancy and prior to 
delivery; 
•	 ensure that all birthing hospitals have appropriate written standing 
orders and/or procedures to test mothers with an unknown HBsAg 
status at the time of delivery; 
•	 make HBsAg-positive test results in pregnant women a reportable 
condition; 
•	 establish links with hospitals and infection control practitioners for 
reporting of all births to HBsAg-positive women; 
•	 consider requirements to document maternal HBsAg status on the 
newborn metabolic screening card or birth certificate; 
•	 assure that health care practitioners, health care organizations, and 
perinatal HBV prevention programs have appropriate policies and 
procedures for active tracking and/or case-management of infants 
born to HBsAg-positive mothers; 
•	 assure testing of all infants born to HBV-infected women for HBsAg 
and anti-HBs at 9 to 15 months of age; and 
•	 establish routine reporting as part of health department case-
management of all HBsAg and anti-HBs test results (positive and 
negative) from infants born to HBsAg-positive women. 
Case Investigation 
Case investigations of suspected cases of perinatal HBV infection 
should be conducted promptly. Information to be collected includes (Table 
IV): 
•	 Serologic test results: Obtain documentation of positive HBsAg 
test results for both the mother and the infant, the age of the child, 
and the child’s country of birth. 
•	 Post-exposure prophylaxis history.  Ascertain the date and 
dosage of HBIG and the date and dosage of all doses of hepatitis B 
vaccine given to the child. 
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•	 Referral for medical evaluation.  Children with HBsAg positive test 
results should be evaluated (by referral or consultation, if 
appropriate) to: 
•	 verify the presence of chronic HBV infection;
•	 assess for biochemical evidence of chronic liver disease; and 
•	 assess for severity of disease and possible treatment according 
to current practice guidelines in consultation with, or by referral 
to, a specialist knowledgeable in this area. 
•	 Revaccination of susceptible infants: Ensure that children who 
test negative for HBsAg and anti-HBs at 9-15 months of age are 
revaccinated.
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Table IV. Components of Perinatal HBV Infection Case Investigations 
Information Collected for Infant Comments/Action
Demographic Information
•	 Sex, date and place of birth, age, 
race/ethnicity 
Diagnostic Test Results 
•	 HBsAg, anti-HBs Testing should be done at 9-15 months of 
age 
If HBsAg positive , refer for medical 
evaluation 
If HBsAg negative and anti-HBs negative, 
revaccinate 
•	 Date of diagnosis 
Immunization History
•	 Date and dosage of HBIG administered 
•	 Date(s) and dosage of hepatitis B vaccine 
administered
Information Collected for Mother 
Demographic information
•	 Age, date of birth, race/ethnicity, country 
of birth
Diagnostic Test Results 
•	 HBsAg 
•	 Date of diagnosis Date of positive HBsAg test 
Results of Case Investigation and Follow-
up 
•	 Date reported to health department 
responsible for case investigation 
•	 Date case investigation initiated Date of first contact with patient and/or health 
care practitioner 
•	  Sexual and household contacts, and needle-At risk contacts identified
sharing contacts of injecting drug users 
•	  Need to assure completion of 3-dose HepBAt risk contacts initiating hepatitis B 
vaccination 	 vaccine series 
•	 Date referred for medical evaluation Evaluate for chronic liver disease, eligibility 
for treatment 
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Reporting to CDC 
Confirmed cases of perinatal HBV infection should be reported to health 
departments as specified by local regulations. Case reports should be 
transmitted weekly by state health departments to CDC using the 
separate NETSS category established for reporting cases of perinatal 
HBV infection.  See Appendix for CDC perinatal HBV case report form. 
Uses of Surveillance Data 
Monitoring the operation and effectiveness of perinatal HBV 
prevention programs: 
The following indicators can be used to monitor the operation and 
effectiveness of perinatal HBV prevention programs and should be 
determined for all infants born to HBV-infected women: 
•	 The proportion of cases that received the first hepatitis B vaccine 

dose <12 hours after birth;
 
•	 The proportion of cases that received the third hepatitis B vaccine 

dose <8 months after birth;
 
• The proportion of cases that received HBIG <12 hours after birth; and
• The proportion of cases that received > 3 hepatitis B vaccine doses. 
Assessing the frequency and causes of immunization failure. 
The frequency of cases occurring in infants who received post exposure 
prophylaxis should be determined to monitor its efficacy. Investigation of 
cases of perinatal HBV infection should be done to evaluate causes of 
possible breakthrough infections and should include obtaining sera from 
the infant and mother to test for the presence of HBV variants. Health 
care professionals who need information regarding testing infants with 
perinatal HBV infection for HBV variants can contact the Perinatal 
Hepatitis B Prevention Program in their state health department or 
CDC’s Division of Viral Hepatitis, National Center for Infectious Diseases 
at 404-371-5910.
Chronic HBV Infection
The objectives and activities of existing state-based databases of 
persons who test positive for HBsAg vary considerably and have not been 
standardized. The following case definition, case ascertainment 
methods, and case investigation and follow-up methods are provided as a 
guide for management of persons who test HBsAg positive. Further 
assessment is needed to determine the most feasible and useful 
approaches to establish these types of systems. 
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Case Definition (*)
Clinical description 
Persons with chronic hepatitis B virus (HBV) infection may be asymptomatic. 
They may have no evidence of liver disease or may have a spectrum of 
disease ranging from chronic hepatitis to cirrhosis or liver cancer. 
Laboratory criteria 
•	 Hepatitis B surface antigen (HBsAg) positive, total anti-HBc positive (if 
done) and IgM anti-HBc negative, OR 
•	 HBsAg positive two times at least 6 months apart 
Case classification 
•	 Confirmed. A case that is laboratory confirmed 
*Note: This case definition was approved by CSTE in June 2002. This is the 





HBsAg positive test results by enzyme immunoassay (EIA) that are not 

supported by positive test results for total anti-HBc or IgM anti-HBc 






The primary methods to ascertain cases of chronic HBV infection are: 
•	 Laboratory reporting of all HBsAg-positive results to state and/or 

local health departments 

•	 Make HBsAg-positive test results a reportable condition. All positive 

HBsAg test results should be followed-up to determine if the person 

has chronic HBV infection (see case definition above). Particular 

efforts should be made to follow-up women of reproductive age. 

Case Investigation and Follow-up 
Case investigation and follow-up should be conducted for persons with 
HBsAg-positive laboratory results and should include (Table V.): 
•	 Serologic test results. A single HBsAg positive and total anti-HBc 

positive test result in an asymptomatic person that is simultaneously 

negative for IgM anti-HBc confirms chronic infection. Chronic HBV 

infection can also be verified by two or more HBsAg positive test 

results separated by at least 6 months. The results of prior hepatitis 

test results should be reviewed if available. 

•	 Pregnancy status for women of childbearing age. All HBsAg-
positive pregnant women should be reported to the Perinatal 

Hepatitis B Prevention Program Manager to ensure that infants born 
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to these women receive appropriate postexposure management 
according to existing ACIP recommendations 33. 
• Immunoprophylaxis and counseling to prevent transmission.
HBsAg-positive persons should be advised regarding how to reduce 
their risk of transmitting HBV to others, including notifying their 
sexual, household, and other (e.g., needle-sharing contacts of IDUs) 
contacts at risk of the need to get vaccinated against hepatitis B. 35 
•	 Counseling and referral. HBsAg-positive persons should be 
advised regarding how to reduce their risk of liver injury and referred 
for medical evaluation and management 35.
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Table V. Components of case investigations of persons testing HBsAg-positive
 Information Collected Comments/Action
Clinical data
•	 Pregnancy status (if female) If yes, report to State Perinatal Hepatitis B 
Prevention Program 
Risk factors (lifetime history)* 
•	 Hemodialysis 
•	 Injection drug use 
•	 Number of sex partners 
•	 Contact with a person who had hepatitis If yes, type of contact (sexual, household, 
casual) 
•	 Employment involving contact with human If yes, degree of blood contact (several 
blood time weekly/infrequent) 
•	 Incarceration 
Results of Case Investigation and Follow-up 
•	 Date reported to health department 
responsible for case investigation 
•	 Date case investigation initiated Date of first contact with patient and/or 
health care practitioner 
• 	 Sexual contacts, household contacts, and At risk contacts identified
needle-sharing contacts of injecting drug 
users 
• 	 Need to assure completion of 3-doseAt risk contacts initiating hepatitis B 
vaccination 	 HepB vaccine series 
•	 Date referred for medical evaluation Evaluate for chronic liver disease, 
eligibility for treatment 
*The collection of risk factor information is not recommended for individuals belonging to groups 
in which most chronic HBV infections are attributable to perinatal or early childhood infection 
with HBV (e.g. emigrants from countries endemic for HBV).  The routine collection of risk factor 
information for other individuals is not required but may provide useful information for the 
development and evaluation of programs to identify and counsel HBV-infected persons.
Reporting to CDC
Cases of chronic HBV infection should be reported to CDC through the 
NNDSS. Inclusion of chronic HBV infection in the list of nationally 
reportable conditions is pending CSTE approval. 
Uses of Surveillance Data. 
Databases of HBsAg-positive persons should be established to 
distinguish newly reported cases of chronic HBV infection from previously 
identified cases. Periodic analyses of the cumulative number of persons 
with HBV infection included in these databases could be used to provide 
local, state and national estimates of the proportion of persons with HBV 
infection who have been identified. 
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Acute Hepatitis C 
Case Definition(*)
Clinical criteria
An acute illness with 
•	 discrete onset of symptoms consistent with acute viral 
hepatitis, and 
•	 jaundice or elevated serum aminotransferase levels 
Laboratory criteria 
•	 Serum alanine aminotransferase levels >7 times the upper 
limit of normal, and 
•	 IgM anti-HAV negative (if done), and 
•	 IgM anti-HBc negative , or if not done, HBsAg negative and 
•	 Antibody to hepatitis C virus (anti-HCV) positive (repeat 
reactive) by EIA, verified by an additional more specific assay 
(e.g. RIBA™ for anti-HCV or nucleic acid testing for HCV RNA) 
OR 
Anti-HCV positive (repeat reactive) by screening immunoassay 
with a signal to cut-off ratio predictive of a true positive as 
determined for the particular assay (e.g., >3.8 for enzyme 
immunoassay). 
Case classification 
Confirmed: A case that meets the clinical case definition and is 
laboratory confirmed. 
Comment 
1) Up to 10% of cases of acute hepatitis C will be anti-HCV negative 
when tested initially because some have not yet seroconverted and 
others (<3%) remain negative even with prolonged follow-up. 
2) Available serologic tests for anti-HCV do not distinguish between 
acute and chronic or past infection. Thus, other causes of acute 
hepatitis should be excluded for anti-HCV positive patients who have 
an acute illness compatible with hepatitis. 
3) The diagnosis of HCV infection can be made by detecting HCV RNA 
using gene amplification techniques (e.g. RT-PCR). However, a 
negative HCV RNA test result does not exclude the possibility of HCV 
infection. 
*This case definition was approved by CSTE in June, 2003. It has been 
updated from the previously published case definition. 
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Case Ascertainment
The primary method to ascertain suspected cases of acute 
hepatitis C is by follow-up of reported clinical cases of hepatitis C and 
non-A, non-B hepatitis. This includes: 
•	 Serologic testing of patients with signs/symptoms of acute viral 
hepatitis, according to an appropriate algorithm (see section on case 
ascertainment). 
•	 Repeat anti-HCV testing, or testing for HCV RNA by RT-PCR, of 
persons with suspected acute viral hepatitis who test negative for IgM 
anti-HAV, IgM anti-HBc, and anti-HCV at the time the case is 
reported. 
Laboratory reporting of anti-HCV positive results is encouraged as 
a method to identify persons with HCV infection. However, most HCV-
infected persons who are identified on the basis of anti-HCV positive 
laboratory reports have chronic, rather than acute, infections. Thus, the 
investigation of these reports is not likely to be an efficient mechanism to 
identify acute hepatitis C cases unless additional clinical information is 
obtained with the serologic result. Routine reporting of ALT levels with 
anti-HCV positive laboratory results might be useful to identify persons 
who are most likely to have acute disease, and would enhance the 
usefulness of laboratory reporting in conducting surveillance for acute 
hepatitis C. 
Case Investigation
Case investigations should be conducted of suspected cases of acute 
hepatitis C and should include (Table VI): 
•	 Clinical features. Determine the date of illness onset, whether 
jaundice or other symptoms consistent with acute viral hepatitis 
were present and the results of testing for aminotransferase 
levels. If possible, evaluate previous medical history for evidence 
of past infection to assess likelihood that current symptoms are 
due to a newly acquired infection. 
•	 Diagnostic test results: Serologic confirmation of acute hepatitis 
C requires negative test results for IgM anti-HAV and IgM anti-
HBc and a positive test result for anti-HCV by EIA verified by a 
positive test result from an additional more specific assay (e.g., 
RIBA™ for anti-HCV or RT-PCR for HCV RNA), or by an average 
EIA signal to cutoff ratio of >3.8. 
•	 Risk factors for infection. (Table VI) All confirmed cases of 
acute hepatitis C should be interviewed to identify a risk factor(s) 
for infection during the 2 weeks to 6 months prior to illness onset. 
•	 Pregnancy status of HCV-infected women of childbearing 
age. No post-exposure prophylaxis is available to prevent 
perinatal transmission of HCV. Children born to anti-HCV positive 
women should be tested for infection.19 
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•	 Counseling and referral for follow-up   Persons with acute 
hepatitis C should be advised regarding how to reduce their risk of 
transmitting HCV to others and the need for follow-up to 
determine the outcome of their infection 19. 
Table VI. Components of Acute Hepatitis C Case Investigations 
Risk factors 
(in 2 wks-6 mo prior to illness 
onset) 
•	 Contact with a person w/ Type of contact (sexual, household, casual) 
confirmed or suspected HCV 
infection 
•	 Employment involving contact Assess degree of blood contact 
with human blood (frequent/infrequent) 
•	 Receipt of blood transfusion or Determine product(s) received, date(s) of 
blood products administration, notify transfusion service 
•	 Dialysis or kidney transplant Notify and investigate facility 
•	 Injecting drug use Refer injecting drug use contacts for counseling 
and testing 
• Number of different male sex 
partners 
Refer all sex contacts for counseling and testing 
partners 
•	 Number of different female sex 
•	 Hospitalization and/or surgery 
Determine if additional cases are linked to same 
injections received in an 
•	 Intravenous infusions or 
facility; assess need for investigation for a 

outpatient setting 
 nosocomial source of infection 
•	 Residence in long-term care 
facility (e.g. nursing home) 
•	 Dental work/oral surgery 
•	 Acupuncture/tattooing/body 
piercing 
• Puncture with a needle or other 
object contaminated w/ blood 
Case Investigation and Follow-up 
•	 Date reported to health 
department responsible for case 
investigation 
•	 Date case investigation initiated Date of first contact with patient and/or health care 
practitioner 
•	 At-risk contacts identified and Sex partners, injecting drug use contacts 
referred for counseling and 
testing 
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Reporting to CDC
Case reports of acute hepatitis C are transmitted weekly by state health 
departments to CDC via NETSS. See Appendix X for CDC case report 
form.
Uses of Surveillance Data
Identifying outbreaks Identification of any of the following risk factors in 
persons with acute hepatitis C should prompt an investigation to 
determine if additional cases are associated with a common source of 
transmission: 
•	 Receipt of blood or blood products. When cases are identified in 
persons who received a blood transfusion during the incubation 
period, the transfusion service and the blood collection 
establishment should be notified. For those patients who have no 
other recognized risk factors for infection, the blood collection 
establishment should identify and retest the donor(s) for evidence of 
HCV infection. For persons who received plasma-derived products 
during the incubation period, the specific product name and lot 
number should be obtained. 
•	 Hemodialysis. The patient’s dialysis unit should be contacted to 
determine if additional cases have been detected. Current policies 
of the unit should be determined regarding routine testing of patients 
for ALT and anti-HCV as well as infection control practices. The unit 
should be provided with appropriate recommendations to prevent 
transmission of HCV and other bloodborne pathogens in the facility34 
.
•	 Hospitalization, surgery, other medical or dental procedures.  For 
persons who report a history of hospitalization, surgery, and/or 
dental procedures, and who have no other recognized risk factors 
for infection, additional information should be obtained regarding the 
specific medical care provider(s) and setting (e.g., hospital, clinic) 
involved. The occurrence of at least two cases associated with the 
same medical care provider or setting or one case with no other risk 
factors should prompt an investigation to determine if there is a 
nosocomial source of infection. 
Monitoring trends in disease incidence and determining risk factors 
for infection Acute hepatitis C surveillance data should be analyzed at 
regular intervals by time, place and person to monitor disease incidence. 
The proportion of cases with specific risk factors should be determined to 
monitor disease transmission patterns. 
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Hepatitis C Virus Infection, (Past or present)
The objectives and activities of existing state-based databases of 
persons reported as anti-HCV positive vary considerably and have not 
been standardized. The following case definition, case ascertainment 
methods, and case investigation and follow-up methods are provided as a 
guide for management of persons who test anti-HCV positive. However, 
further evaluation is needed to determine the most feasible and useful 
approaches to establish these types of systems. 
Case Definition  (*) 
Clinical description 
Most HCV-infected persons are asymptomatic. However, many 
have chronic liver disease, which can range from mild to severe 
including cirrhosis, and liver cancer. 
Laboratory criteria 
•	 Anti-HCV positive (repeat reactive) by EIA, verified by an 
additional more specific assay (e.g. RIBA for anti-HCV or nucleic 
acid testing for HCV RNA) 
Or 
•	 Anti-HCV positive (repeat reactive) by EIA with a signal to cut-off 
ratio predictive of a true positive as determined for the particular 
assay (e.g., ≥3.8 for the enzyme immunoassays). 
Case Classification
Confirmed. A case that is laboratory confirmed. 
Probable. A case that is anti-HCV positive (repeat reactive) by 
EIA and has alanine aminotranferase (ALT or SGPT) values 
above the upper limit of normal, but the anti-HCV EIA result has 
not been verified by an additional more specific assay or the 
signal to cut-off ratio is unknown.
*Note: This case definition was approved by CSTE in June 2002 
and is the first published for HCV infection. 
Case Ascertainment 
The primary method to ascertain cases of HCV infection is by reporting of 
all anti-HCV positive laboratory results to state and/or local health 
departments. 
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Case Investigation and Follow-up
Case investigation and follow-up should be conducted for persons with 
anti-HCV positive laboratory results and should include (Table VII.) 
•	 Serologic test results. The diagnosis of HCV infection in a person 
testing positive for anti-HCV by EIA should be confirmed by an
additional more specific assay (e.g., RIBA for anti-HCV or RT-PCR 
for HCV RNA). However, if test results by an additional more specific 
assay are not available, a person who tests positive for anti-HCV by 
EIA with an average signal to cut-off ratio >3.8 can also be reported 
as confirmed. An anti-HCV positive person who has elevated liver 
enzyme levels but for whom additional confirmatory data are 
unavailable should be reported as a probable case. 
•	 Counseling and referral for medical management. HCV-infected 
persons should be advised regarding how to reduce their risk of 
transmitting HCV to others and how to reduce further liver injury. 
They should also be referred for medical evaluation and 
management19. 
Reporting to CDC
Cases of Hepatitis C virus infection should be reported to CDC 
through the NNDSS. Inclusion of HCV infection, chronic or resolved in 
the list of nationally reportable conditions is pending CSTE approval. 
Uses of Surveillance Data 
Periodic analyses of the cumulative number of persons 
enrolled in HCV infection databases could be used to provide local, state 
and national estimates of the proportion of persons with HCV infection 
who have been identified. Recommended information elements to be 
maintained in such databases are described in Appendix. 
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Table VII. Components of HCV Infection Case Investigations 
Information Collected Comments/Action
Clinical data
•	 Pregnancy status (if female) If yes, provide counseling regarding risks of 
transmission from mother to infant. Arrange follow-up 
of infant to test for infection. Consider testing other 
children for infection 
•	 Reason for testing
Diagnostic Test Results
Obtain most recent and prior diagnostic test results•	 Anti-HCV (EIA) 
for HCV infection (if available), including dates of 
testing 
•	 Anti-HCV (RIBA™) 
•	 HCV RNA 
• Date of diagnosis 	 Date of first positive anti-HCV test
Risk factors (lifetime history)* 
•	 Blood transfusion prior to 1992 
•	 Organ transplant prior to 1992 
•	 Receipt of clotting factor 
concentrates made prior to 
1987 
•	 Hemodialysis 
•	 Injection drug use 
•	 Number of sex partners 
•	 Contact with a person who had If yes, type of contact (sexual, household, casual) 
hepatitis 
•	 Employment involving contact If yes, degree of blood contact (several times 
with human blood weekly/infrequent) 
Case Investigation and Follow-
up 
•	 Date reported to health 
department responsible for 
case investigation 
•	 Date case investigation First contact with patient and/or health care 
initiated practitioner 
•	 Date referred for medical Evaluate for chronic liver disease, eligibility for 
evaluation treatment 
*Routine collection of risk factor information for persons who test HCV positive is not required.  
However, collection of risk factor information for such persons may provide useful information 
for the development and evaluation of programs to identify and counsel HCV-infected persons 
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Acute non-ABC hepatitis 
Surveillance for non-ABC hepatitis is needed to identify and 
monitor the frequency of disease that may be associated with other 
known agents of viral hepatitis (HDV and HEV) and to detect new 
etiologic agents. Individuals with signs and symptoms of acute viral 
hepatitis who are negative for serologic markers of acute hepatitis A (IgM 
anti-HAV), acute hepatitis B (IgM anti-HBc) and hepatitis C (anti-HCV) 
should be reported via the state health department to CDC and further 
investigation to describe the characteristics of the case and to identify a 
causal agent may be considered. Health-care professionals who need 
information on additional testing of persons with acute non-ABC hepatitis 
may contact CDC’s Division of Viral Hepatitis, National Center for 
Infectious Diseases at (404) 371-5910. 
OTHER SURVEILLANCE METHODS 
Serologic Surveys  
Many persons with new HAV, HBV, and HCV infections, 
particularly young children, are asymptomatic and many cases of 
symptomatic disease are not reported to the Nationally Notifiable Disease 
Surveillance System. Thus, serosurveys are needed to assess the extent 
of the disease burden associated with viral hepatitis and to monitor the 
impact of prevention and control programs. National seroprevalence data 
for HAV, HBV, and HCV infections are provided by the CDC National 
Health and Nutrition Examination Survey (NHANES), a periodic survey of 
a sample of the civilian, non-institutionalized U.S. population. However, 
NHANES can provide only regional seroprevalence estimates and the 
survey does not have an adequate sample size for some population 
groups that are at high risk of viral hepatitis. Thus, selected serosurveys 
conducted at the state and local level and of specific population groups 
are needed to measure the effectiveness of prevention and control 
programs. 
Chronic Liver Disease Surveillance 
Surveillance for HBV and HCV-related chronic liver disease can provide 
information to measure the burden of disease, determine natural history 
and risk factors, and develop and evaluate the effect of therapeutic and 
prevention measures on incidence and severity of disease. Recently, a 
sentinel surveillance pilot program for physician-diagnosed chronic liver 
disease was established which will provide baseline data and a template 
for a broader surveillance system for chronic liver disease. As the primary 
source of data regarding the incidence and natural history of chronic liver 
disease, this network will be pivotal for monitoring the effects of 
education, counseling, other prevention programs, and newly developed 
therapies on the burden of the disease. 
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Was this record submitted to CDC through the NETSS system?  Yes  No 
If yes, please enter NETSS ID NO.  If no, please enter STATE CASE NO. 
RACE (check all that apply):
 Amer Indian or Alaska Native Black or African American White




Other/Unknown .........SEX: Male Female Unk 





AGE: ___ ___ (years) ( 00= <1yr , 99= Unk ) __ __ / __ __ / __ __ __ __M M D D Y Y Y Y 




12345678901234567890123456789012123456789012345678901234567890121234567890123456789012345678901212345CLINICAL & DIAGNOSTIC DATA 
12345678901234567890123456789012123456789012345678901234567890121234567890123456789012345678901212345
REASON FOR TESTING: (Check all that apply)  Symptoms of acute hepatitis Evaluation of elevated liver enzymes 
Screening of asymptomatic patient with reported risk factors Blood / organ donor screening 
Screening of asymptomatic patient with no risk factors (e.g., patient requested ) Follow-up testing for previous marker of viral hepatitis 
Prenatal screening Unknown Other: specify: ____________ 
    
U.S. DEPARTMENT OF CDCHEALTH & HUMAN SERVICES VIRAL HEPATITIS CASE REPORT Centers for Disease ControlPUBLIC HEALTH SERVICE and Prevention 
Hepatitis Branch, (G37) 
Atlanta, Georgia 30333The following questions should be asked for every case of viral hepatitis 
Prefix: (Mr. Mrs. Miss Ms. etc) ______ Last: ______________________________ First: _________________________ Middle: _________________ 
DRAFT COPY DRAFT COPY 
      
  
          






Preferred Name (nickname): _________________________________  Maiden: _________________________________________________________ 
Address: Street: ________________________________________________________________________________________________________________ 
City: ________________________________________________ Phone: ( ) - Zip Code: ___ ___ ___ ___ ___ -- ___ ___ ___ ___
 SSN # (optional) ___ ___ __ - ___ ___ - ___ ___ ___ ___ 
Only data from lower portion of form will be transmitted to CDC 
State: _______________ County: ______________________________________________ Date of Public Health Report__ __ / __ __ / __ __ __ __
 k
   
           
  
• If this case has a diagnosis of hepatitis A that has not been 
serologically confirmed, is there an epidemiologic link between 
this patient and a laboratory-confirmed hepatitis A case? ............ 
 
LIVER ENZYME LEVELS AT TIME OF DIAGNOSIS 
• ALT [SGPT] Result ______  Upper limit normal_______ 
• AST [SGOT] Result ______ Upper limit normal_______ 
• Date of ALT result M M D D Y Y Y Y__ __ / __ __ / __ __ __ __ 
Yes  No Unk 
     • Date of AST result M M D D Y Y Y Y__ __ / __ __ / __ __ __ __ 
DIAGNOSIS: (Check all that apply) 
Acute hepatitis A 
Acute hepatitis B Chronic HBV infection Perinatal HBV infection Hepatitis Delta (co- or super-infection) 
Acute hepatitis C HCV infection (chronic or resolved)
 
Acute hepatitis E
 Acute non-ABCD hepatitis 
1 
C:\My Documents\Projects\Hepatitis\VHSPW.p65 
CLINICAL DATA: DIAGNOSTIC TESTS: CHECK ALL THAT APPLY 
Pos Neg Un
• Total antibody to hepatitis A virus  [total anti-HAV] ................ 
• IgM antibody to hepatitis A virus [IgM anti-HAV] ..................... 
• Hepatitis B surface antigen [HBsAg] ............................................. 
• Total antibody to hepatitis B core antigen [total anti-HBc] ..... 
• IgM antibody to hepatitis B core antigen [IgM anti-HBc] ......... 
• Antibody to hepatitis C virus [anti-HCV] ................................... 
- anti-HCV signal to cut-off ratio __________ 
• Supplemental anti-HCV assay [e.g., RIBA] .............................. 
• HCV RNA [e.g., PCR] ..................................................................... 
• Antibody to hepatitis D virus [anti-HDV] ................................... 
• Antibody to hepatitis E virus [anti-HEV] ................................... 
M M     D D  Y  Y  Y Y • Date of death:  __ __ / __ __ / __ __ __ __ 
Did the patient die from hepatitis? .......................... 
M M  D  D  Y  Y  Y Y__ __ / __ __ / __ __ __ __
 Yes No Unk 
Was the patient 
• Jaundiced? ............................................................... 
• Hospitalized for hepatitis? .................................... 
Was the patient pregnant ? ....................................... 
due date : 
Diagnosis date: 
Is patient symptomatic? ........................................... 
if yes, onset date: 
M M  D  D  Y  Y  Y Y__ __ / __ __ / __ __ __ __









      
 
            
      
 
      











Patient History- Acute Hepatitis A NETSS ID NO. 
STATE CASE NO. _________________________________________ 
During the 2-6 weeks prior to onset of symptoms­ Yes No Unk 
Was the patient a contact of a person with confirmed or suspected 
hepatitis A virus infection? ................................................................................................. 
If yes, was the contact (check one) 
• household member (non-sexual) ................................................................................... 
• sex partner ...................................................................................................................... 
• child cared for by this patient ....................................................................................... 
• babysitter of this patient ............................................................................................... 
• playmate .......................................................................................................................... 
• other _____________________________________ 
Was the patient 
• a child or employee in a day care center, nursery, or preschool ? .......................... 
• a household contact of a child or employee in a 
day care center, nursery or preschool ? .................................................................... 
If yes for either of these, was there an identified hepatitis A case 
in the child care facility? ............................................................................................
 0 1 2-5 >5 Unk 
Please ask both of the following questions regardless of the patient’s gender. 
In the 2- 6 weeks before symptom onset how many 
• male sex partners did the patient have? .................................................... 
• female sex partners did the patient have? ................................................ 
Did the patient inject drugs not prescribed by a doctor? ............................................. 
Did the patient use street drugs but not inject? ............................................................
 Yes No UnkIn the 2- 6 weeks before symptom onset 
Was the patient employed as a food handler during the TWO WEEKS 
prior to onset of symptoms or while ill? ..............................................................................
 Is the patient suspected as being part of a common-source outbreak? .......................... 
If yes, was the outbreak 
Foodborne- associated with an infected food handler ................................................ 
Foodborne - NOT associated with an infected food handler .................................... 
• specify food item _____________________________________ 
Waterborne ...................................................................................................................... 
Source not identified ....................................................................................................... 
Has the patient ever received immune globulin ? ........... 
• If yes, when was the last dose received? ...................... ______ / _____ 
VACCINATION HISTORY 
Has the patient ever received the hepatitis A vaccine ? 
• If yes, how many doses? ................................................ 
• In what year was the last dose received? .................. Y
 Yes No Unk 
YY
 1 ≥≥2
 Yes No Unk 
mo  yr 
Y 
In the 3 months prior to symptom onset 
Did anyone in the patient’s household travel outside of the U.S. A. or Canada? 
• If yes, where? 1) _________________ 2) _________________ 
(Country) 3) _________________ 
Did the patient travel outside of the U.S.A. or Canada ............................................. 
• If yes, where? 1) _________________ 2) _________________ 
(Country) 3) _________________ 
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STATE CASE NO. _________________________________________ 
Patient History- Acute Hepatitis B NETSS ID NO. 
During the 6 weeks- 6 months prior to onset of symptoms 
was the patient a contact of a person with confirmed or 
suspected acute or chronic hepatitis B virus infection? 
If yes, type of contact 
• Sexual ......................................................................... 
• Household [Non-sexual] .......................................... 
• Other: _______________________________
 Yes No Unk 
Ask both of the following questions regardless of the patient’s gender. 
In the 6 months before symptom onset how many 
• male sex partners did the patient have? ............... 
• female sex partners did the patient have? ........... 
0 1 2-5 >5 Unk 
Y  Y  Y  Y 
Was the patient EVER treated for a sexually­
transmitted disease? ............................................................... 
• If yes, in what year was the most recent treatment ? __ __ __ __
 Yes No Unk 
• inject drugs not prescribed by a doctor? ........................ 
• use street drugs but not inject? ....................................... 
During the 6 weeks- 6 months prior to onset of symptoms 
Was the patient tested for antibody to HBsAg 
(anti-HBs) within 1-2 months after the last dose? ....... 
• If yes, was the serum anti-HBs ≥≥ 10mIU/ml? .................... 
(answer ‘yes’ if the laboratory result was reported as ..... 
‘positive’ or ‘reactive’)
 Yes No Unk 
Did the patient ever receive hepatitis B vaccine? 
If yes, how many shots? ........................................... 
• In what year was the last shot received? ..................
 Yes No Unk
 Yes No Unk 
During his/her lifetime, was the patient EVER 
• incarcerated for longer than 6 months ? ........................... 
• If yes, 
what year was the most recent incarceration ? .................... 
for how long ? ..................................................................... __ __ __ mos 
Y Y Y Y 
• Did the patient have dental work or oral surgery? ............. 
• Did the patient have surgery ? (other than oral surgery) .. 
• Was the patient- Check all that apply 
• hospitalized ? ............................. 
• a resident of a long term care facility ? ........................... 
• incarcerated for longer than 24 hours ? ..........................
 if yes, what type of facility (check all that apply) 
prison .............................................................. 
jail .................................................................... 
juvenile facility .............................................. 
• Did the patient have any part of their body pierced
 (other than ear)? 
where was the piercing performed? (select all that apply) 
commercial correctional other ________________ 
parlor / shop facility 
During the 6 weeks- 6 months prior to onset of symptoms 
Did the patient­
• undergo hemodialysis? ................................................... 
• have an accidental stick or puncture with a needle 
or other object contaminated with blood? ............... 
• receive blood or blood products [transfusion] ............ 
• if yes, when? M M / D D / Y Y Y Y 
• have other exposure to someone else’s blood ............ 
specify: ____________________________________ 
Yes No Unk 
During the 6 weeks- 6 months prior to onset of symptoms 
During the 6 weeks - 6 months prior to onset of symptoms 
• Was the patient employed in a medical or dental field 
involving direct contact with human blood ? ............... 
If yes, frequency of direct blood contact? 
Frequent (several times weekly) Infrequent 
• Was the patient employed as a public safety worker 
(fire fighter, law enforcement or correctional officer) 
having direct contact with human blood? .......................... 
If yes, frequency of direct blood contact? 
Frequent (several times weekly) Infrequent 
__ __ __ __ 
• Did the patient receive a tattoo? ................................... 
where was the tattooing performed? (select all that apply) 
commercial correctional other ________________ 
parlor / shop facility 
Y YYY
 1  2  3+ 





      








Perinatal Hepatitis B Virus Infection	 NETSS ID NO. 
STATE CASE NO.  _________________________________________ 
RACE OF MOTHER:	 ETHNICITY OF MOTHER: 
Amer Ind or Alaska Native Black or African American White Unknown Hispanic .................... 




Yes No Unk 
Was Mother born outside of United States? .................................................................
 If yes, what country?___________________ 
Was the Mother confirmed HBsAg positive prior to or at time of delivery ? ... 
• If no, was the mother confirmed HBsAg positive after delivery? ....................
 
Date of HBsAg positive test result .................................................................................... M M / D D / Y Y Y Y
 
How many doses of hepatitis B vaccine did the child receive ? ..................................
 0  1  2  3 
• When? 
• Dose 1- M M / D D / Y Y Y Y 
• Dose 2- M M / D D / Y Y Y Y 
• Dose 3- M M / D D / Y Y Y Y 
Yes No Unk 
Did the child receive hepatitis B immune globulin (HBIG)? .......................................
 





      
        





   
    
  
NETSS ID NO. 
Patient History- Acute Hepatitis C STATE CASE NO.  _________________________________________ 
During the 2 weeks- 6 months prior to onset of symptoms 
was the patient a contact of a person with confirmed or 
suspected acute or chronic hepatitis C virus infection? 
If yes, type of contact 
• Sexual ......................................................................... 
• Household [Non-sexual] .......................................... 
• Other: _______________________________
 Yes No Unk 
Ask both of the following questions regardless of the patient’s gender. 
In the 6 months before symptom onset how many 
• male sex partners did the patient have? ............... 
• female sex partners did the patient have? ...........
 0 1 2-5 >5 Unk 
Y  Y  Y  Y 
Was the patient EVER treated for a sexually 
transmitted disease? .................................................................... 
• If yes, in what year was the most recent treatment ? __ __ __ __
 Yes    No  Unk 
• inject drugs not prescribed by a doctor? ........................ 
• use street drugs but not inject? ....................................... 
During the 2 weeks- 6 months prior to onset of symptoms
 Yes No Unk 
• Did the patient have any part of their body pierced
 (other than ear)? 
where was the piercing performed? (select all that apply) 
commercial correctional other ________________ 
parlor / shop facility
 Yes   No   Unk 
During the 2 weeks- 6 months prior to onset of symptoms 
During the 2 weeks - 6 months prior to onset of symptoms 
• Was the patient employed in a medical or dental field 
involving direct contact with human blood ? ............... 
If yes, frequency of direct blood contact? 
Frequent (several times weekly) Infrequent 
• Was the patient employed as a public safety worker 
(fire fighter, law enforcement or correctional officer) 
having direct contact with human blood? .......................... 
If yes, frequency of direct blood contact? 
Frequent (several times weekly) Infrequent 
During his/her lifetime, was the patient EVER 
• incarcerated for longer than 6 months ? ........................... 
• If yes, 
what year was the most recent incarceration ? .................... 
for how long ? ..................................................................... __ __ __ mos 
__ __ __ __Y Y YY 
• Did the patient have dental work or oral surgery? ............. 
• Did the patient have surgery ? (other than oral surgery) .. 
• Was the patient- Check all that apply 
• hospitalized ? ............................. 
• a resident of a long term care facility ? ........................... 
• incarcerated for longer than 24 hours ? ..........................
 if yes, what type of facility (check all that apply) 
prison .............................................................. 
jail .................................................................... 
juvenile facility .............................................. 
• Did the patient receive a tattoo? ................................... 
where was the tattooing performed? (select all that apply) 
commercial correctional other ________________ 
parlor / shop facility 
During the 2 weeks- 6 months prior to onset of symptoms 
Did the patient­
• undergo hemodialysis?  ................................................... 
• have an accidental stick or puncture with a needle 
or other object contaminated with blood?  ............... 
• receive blood or blood products [transfusion]  ............ 
• if yes, when? M M / D D / Y Y Y Y 
• have other exposure to someone else’s blood  ............ 
specify: ____________________________________ 
• receive any IV infusions and/or injections in the outpatient setting... 
3 





NETSS ID NO. 
Patient History- Hepatitis C Virus Infection (chronic or resolved) 
STATE CASE NO.  _________________________________________ 
The following questions are provided as a guide for the investigation of lifetime risk factors for HCV infection. Routine collection of risk factor
 
information for persons who test HCV positive is not required. However, collection of risk factor information for such persons may provide useful
 
information for the development and evaluation of programs to identify and counsel HCV-infected persons.
 
Yes No UnkYes No Unk
• Did the patient receive a blood transfusion prior to 1992? ...................
 • Was the patient ever employed in a medical or 
• Did the patient receive an organ transplant prior to 1992? .............................
 dental field involving direct contact with human 
• Did the patient receive clotting factor concentrates produced prior to 1987? blood? ....................................................................
 
• Was the patient ever on long-term hemodialysis? ..........................................
 
• Has the patient ever injected drugs not prescribed by a doctor 
even if only once or a few times? ............................................................
• How many sex partners has the patient had (approximate lifetime) ? _________ 
• Was the patient ever incarcerated? .............................................................
 
• Was the patient ever treated for a sexually transmitted disease? .............
 
•	 Was the patient ever a contact of a person who had hepatitis ? .......... 
If yes, type of contact 
•	 Sexual .........................................................................................................
 
• Household [Non-sexual] ............................................................................
 
•	 Other: ____________________________________ 
